Checkpoint Therapeutics
2014
FOUNDED
PUBLIC
STATUS
1-10
EMPLOYEES
CKPT
STOCK SYMBOL
$1.27
SHARE PRICE
(As of Thursday Closing)
Description
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP).
Ownership Status
Publicly Held
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
- 3 Columbus Circle
- 15th Floor
- New York, NY 10019
- United States
+1 (781) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Checkpoint Therapeutics’s full profile, request a free trial.
Checkpoint Therapeutics Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $1.12 - $5.20 | $48.5M | $1.18 | -$0.86 | 150K | 38.2M |
Checkpoint Therapeutics Financials Summary
|
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 81,404 | 32,365 | 75,553 | |
| Revenue | 4,714 | 3,506 | 1,725 | 2,570 |
| EBITDA | (27,660) | (36,515) | (22,775) | (22,164) |
| Net Income | (27,507) | (36,367) | (22,677) | (22,461) |
| Total Assets | 14,080 | 24,899 | 21,413 | 35,978 |
| Total Debt | 0 | 0 | 0 | 0 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Checkpoint Therapeutics Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Checkpoint Therapeutics‘s full profile, request access.
Request full access to PitchBookCheckpoint Therapeutics Competitors (8)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Metacrine | Venture Capital-Backed | San Diego, CA | 00 | 00000 | 000000000 | 00000 |
| 000000000 | Formerly VC-backed | South San Francisco, CA | 00000 | 000.00 | 00000000000 | |
| 00000000 000000000 | Corporation | West Conshohocken, PA | 00 | 000.00 | 000000 - 000 | 000.00 |
| 00000 | Venture Capital-Backed | Pittsburgh, PA | 00 | 000.00 | 0000000000 0 | 000.00 |
| 000000 00000000000 | Venture Capital-Backed | Cambridge, MA | 00 | 00000 | 0000000000 0 | 00000 |
Checkpoint Therapeutics Executive Team (2)
| Name | Title | Board Seat |
Contact Info |
|---|---|---|---|
| James Oliviero III | Chief Executive Officer & Board Member | ||
| David Horin | Interim Chief Financial Officer |
Checkpoint Therapeutics Board Members (1)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| 00000 00000000 000 | Checkpoint Therapeutics | Chief Executive Officer & Board Member | 000 0000 |